tradingkey.logo

Street View: Merck signals renewed confidence in growth after Keytruda patent loss

ReutersJan 13, 2026 11:35 AM

Merck on Monday raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by mid-2030s as it navigates looming competition to its blockbuster cancer therapy Keytruda

NEW YEAR AND A NEW MERCK

Bernstein ("market perform," PT: $95) says Keytruda patent loss remains "the industry's largest challenge", potentially affecting about 50% of revenue

Says Merck showcased clearer navigation plan and stronger visibility into its pipeline and that it is open to deals potentially in "multi‑tens of billions" category

BMO Capital Markets ("outperform," PT: $130) says Merck's commentary at J.P. Morgan Healthcare Conference around managing Ketruda LOE "projects new confidence we have not heard recently"

Adds that raised outlook is "broadly supportive of the opportunity we see with recent deals"

Citi ("neutral"," PT: $110) says Merck is "making solid progress towards offsetting the patent impact but is not yet in the clear"

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI